Effects of azole antifungal drugs on the transition from yeast cells to hyphae in susceptible and resistant isolates of the pathogenic yeast Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 763-768

  Ha, Kien C ^a   White, Theodore C ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; KETOCONAZOLE;

ARTICLE; CANDIDA ALBICANS; DRUG SENSITIVITY; FUNGUS GROWTH; FUNGUS HYPHAE; FUNGUS IDENTIFICATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; YEAST CELL;

EID: 0032942954     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.763     Document Type: Article

References (33)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans flucunazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
2. Borgers, M., and M. A. Van de Ven. 1989. Mode of action of intraconazole: morphological aspects. Mycoses 1:53-59.
3. Cutler, J. E. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:187-218.
4. Galgiani, J., M. Bartlett, M. Espinel-Ingroff, R. Fromtling, M. Pfaller, and M. Rinaldi. 1992. Reference method for broth dilution antifungal susceptibility testing of yeasts: proposed standard, vol. 12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
5. Gallagher, P. J., D. E. Bennett, M. C. Henman, R. J. Russell, S. R. Flint, D. B. Shanley, and D. C. Coleman. 1992. Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation. J. Gen. Microbiol. 138:1901-1911.
6. Greenspan, D., J. Greenspan, M. Schiodt, and J. Pindborg. 1990. AIDS and the mouth, p. 91-102. Munksgaard, Copenhagen, Denmark.
7. Ha, K. C., and T. C. White, Unpublished data.
8. Haller, I. 1985. Mode of action of clotrimazole: implications for therapy. Am. J. Obstet. Gynecol. 152:939-944.
9. Johnson, E. M., M. D. Richardson, and D. W. Warnock. 1983. Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans. J. Antimicrob. Chemother. 12:303-316.
10. Johnson, E. M., M. D. Richardson, and D. W. Warnock. 1984. In-vitro resistance to imidazole antifungals in Candida albicans. J. Antimicrob. Chemother. 13:547-558.
11. Lees, N. D., M. C. Broughton, D. Sanglard, and M. Bard. 1990. Azole susceptibility and hyphal formation in a cytochrome P-450-deficient mutant of Candida albicans. Antimicrob. Agents Chemother. 34:831-836.
12. Marichal, P., J. Gorrens, C. J. Van, and B. H. Vanden. 1986. Culture media for the study of the effects of azole derivatives on germ tube formation and hyphal growth of C. albicans. Mykosen 29:76-81.
13. Marr, K. A., C. N. Lyons, T. Rustad, R. A. Bowden, and T. C. White. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother. 42:2584-2589.
14. Marr, K. A., T. C. White, J. A. H. vanBurik, and R. A. Bowden. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
15. Moran, G. P., D. J. Sullivan, M. C. Henman, C. E. McCreary, B. J. Harrington, D. B. Shanley, and D. C. Coleman. 1997. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41:617-623.
16. Niimi, M., F. J. Fischer, J. Piper, H. F. Jenkinson, M. Arisawa, and R. D. Cannon. 1997. Presented at the 13th Congress of the International Society for Human and Animal Mycology.
17. Odds, F. C. 1988. Candida and Candidosis: a review and bibliography. Bailliere Tindall, London, United Kingdom.
18. Odds, F. C., S. L. Cheesman, and A. B. Abbott. 1986. Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. J. Antimicrob. Chemother. 18:473-478.
19. Odds, F. C., A. Cockayne, J. Hayward, and A. B. Abbott. 1985. Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. J. Gen. Microbiol. 131:2581-2589.
20. Pfaller, M. A., C. J. Rhine, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
21. Prasad, R. 1987. Nutrient transport in Candida alhicans, a pathogenic yeast. Yeast 3:209-221.
22. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, C. J. Rhine, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
23. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14 alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
24. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143: 405-416.
25. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
26. Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
27. Singh, M., A. Jayakumar, and R. Prasad. 1979. The effect of altered ergosterol content on the transport of various amino acids in Candida albicans. Biochim. Biophys. Acta 555:42-55.
28. Staab, J. F., C. A. Ferrer, and P. Sundstrom. 1996. Developmental expression of a tandemly repeated, proline-and glutamine-rich amino acid motif on hyphal surfaces on Candida albicans. J. Biol. Chem. 271:6298-6305.
29. Wakabayashi, H., S. Abe, S. Teraguchi, H. Hayasawa, and H. Yamaguchi. 1998. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemother. 42:1587-1591.
30. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
31. White, T. C. 1997. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
32. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
33. White, T. C., M. A. Pfaller, R. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3:S102-S109.